Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia

Oncotarget

Volumn 8, Issue 7, 2017, Pages 11219-11227

  McMahon, Kaylin M ^a   Scielzo, Cristina ^b,c   Angeloni, Nicholas L ^a   Deiss Yehiely, Elad ^a   Scarfo, Lydia ^b,c   Ranghetti, Pamela ^b,c   Ma, Shuo ^a   Kaplan, Jason ^a   Barbaglio, Federica ^c   Gordon, Leo I ^a   Giles, Francis J ^a   Thaxton, C Shad ^a,d,e   Ghia, Paolo ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Simpson Querrey Institute for BioNanotechnology   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomaterials; Leukemia; Lipoprotein; Nanoparticle; Scavenger receptor type B I

Indexed keywords

HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; SCAVENGER RECEPTOR BI; CD36 ANTIGEN; PROTEIN BINDING;

ARTICLE; CELL DEATH; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN TARGETING; TOXICITY TESTING; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BINDING COMPETITION; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; SYNTHESIS; WESTERN BLOTTING;

ANTIGENS, CD36; APOPTOSIS; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, HDL; MALE; NANOPARTICLES; PROTEIN BINDING;

EID: 85012890002     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14494     Document Type: Article

References (25)

1. Randhawa JK, Ferrajoli A. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2016; 9:235-244.
2. Morabito F, Gentile M, Seymour JF, Polliack A. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. Leuk Lymphoma. 2015; 56:3250-3256.
3. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016; 16:145-162.
4. Mulas MF, Abete C, Pulisci D, Pani A, Massidda B, Dessi S, Mandas A. Cholesterol esters as growth regulators of lymphocytic leukaemia cells. Cell Prolif. 2011; 44:360-371.
5. Gorin A, Gabitova L, Astsaturov I. Regulation of cholesterol biosynthesis and cancer signaling. Curr Opinion in pharmacology. 2012; 12:710-716.
6. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeney LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet. 2011; 43:60-65.
7. de Gonzalo-Calvo D, Lopez-Vilaro L, Nasarre L, Perez-Olabarria M, Vazquez T, Escuin D, Badimon L, Barnadas A, Lerma E, Llorente-Cortes V. Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study. BMC Cancer. 2015; 15:460.
8. Schorghofer D, Kinslechner K, Preitschopf A, Schutz B, Rohrl C, Hengstschlager M, Stangl H, Mikula M. The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence. Reprod Biol Endocrinol. 2015; 13:88.
9. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, Mora EM, Lee JW, Stone RL, Pecot CV, Thanapprapasr D, Roh JW, Gaur P, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011; 13:309-319.
10. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996; 271:518-520.
11. Atshaves BP, McIntosh AL, Payne HR, Gallegos AM, Landrock K, Maeda N, Kier AB, Schroeder F. SCP-2/SCP-x gene ablation alters lipid raft domains in primary cultured mouse hepatocytes. J Lipid Res. 2007; 48:2193-2211.
12. Valacchi G, Sticozzi C, Lim Y, Pecorelli A. Scavenger receptor class B type I: a multifunctional receptor. Ann N Y Acad Sci. 2011; 1229:E1-7.
13. Thuahnai ST, Lund-Katz S, Dhanasekaran P, de la Llera-Moya M, Connelly MA, Williams DL, Rothblat GH, Phillips MC. Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J Bio Chem. 2004; 279:12448-12455.
14. Luthi AJ, Lyssenko NN, Quach D, McMahon KM, Millar JS, Vickers KC, Rader DJ, Phillips MC, Mirkin CA, Thaxton CS. Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein. J Lipid Res. 2015; 56:972-985.
15. Luthi AJ, Zhang H, Kim D, Giljohann DA, Mirkin CA, Thaxton CS. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS nano. 2012; 6:276-285.
16. Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, Ugolkov AV, Singh AT, Dave SS, Gordon LI, Thaxton CS. Biomimetic, synthetic HDL nanostructures for lymphoma. Pro Nat Acad Sci USA. 2013; 110:2511-2516.
17. Plebanek MP, Mutharasan RK, Volpert O, Matov A, Gatlin JC, Thaxton CS. Nanoparticle Targeting and Cholesterol Flux Through Scavenger Receptor Type B-1 Inhibits Cellular Exosome Uptake. Sci Rep. 2015; 5:15724.
18. Angeloni NL, McMahon KM, Swaminathan S, Plebanek MP, Osman I, Volpert OV, Thaxton CS. Pathways for Modulating Exosome Lipids Identified By High-Density Lipoprotein-Like Nanoparticle Binding to Scavenger Receptor Type B-1. Sci Rep. 2016; 6:22915.
19. Sugimoto K, Hayakawa F, Shimada S, Morishita T, Shimada K, Katakai T, Tomita A, Kiyoi H, Naoe T. Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells. Sci Rep. 2015; 5:13054.
20. Meads MB, Gatenby RA, Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9:665-674.
21. Tripathy S, Vinokour E, McMahon KM, Volpert OV, Thaxton CS. High-Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Part Part Syst Charact. 2014; 31:1141-1150.
22. McMahon KM, Mutharasan RK, Tripathy S, Veliceasa D, Bobeica M, Shumaker DK, Luthi AJ, Helfand BT, Ardehali H, Mirkin CA, Volpert O, Thaxton CS. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett. 2011; 11:1208-1214.
23. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic L. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111:5446-5456.
24. Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc. 2009; 131:1384-1385.
25. Faucher JL, Lacronique-Gazaille C, Frebet E, Trimoreau F, Donnard M, Bordessoule D, Lacombe F, Feuillard J. "6 markers/5 colors" extended white blood cell differential by flow cytometry. Cytometry A. 2007; 71:934-944.